advertisement
Abstract #51894 Published in IGR 14-4
Subretinal injection of gene therapy vectors and stem cells in the perinatal mouse eye
Wert KJ; Skeie JM; Davis RJ; Tsang SH; Mahajan VBJournal of Vision Exp 2012; 0:
The loss of sight affects approximately 3.4 million people in the United States and is expected to increase in the upcoming years.(1) Recently, gene therapy and stem cell transplantations have become key therapeutic tools for treating blindness resulting from retinal degenerative diseases. Several forms of autologous transplantation for age-related macular degeneration (AMD), such as iris pigment epithelial cell transplantation, have generated encouraging results, and human clinical trials have begun for other forms of gene and stem cell therapies.(2) These include RPE65 gene replacement therapy in patients with Leber's congenital amaurosis and an RPE cell transplantation using human embryonic stem (ES) cells in Stargardt's disease.(3-4) Now that there are gene therapy vectors and stem cells available for treating patients with retinal diseases, it is important to verify these potential therapies in animal models before applying them in human studies. The mouse has become an important scientific model for testing the therapeutic efficacy of gene therapy vectors and stem cell transplantation in the eye.(5-8) In this video article, we present a technique to inject gene therapy vectors or stem cells into the subretinal space of the mouse eye while minimizing damage to the surrounding tissue.
Bernard and Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia University, USA.
Full articleClassification:
11.9 Gene therapy (Part of: 11 Medical treatment)
